Skip to content
HowShorted

Intra-Cellular Therapies Inc. short interest in 2018

In 2018, Intra-Cellular Therapies Inc.'s disclosed short interest ran from 5.26% of shares outstanding on 12 Jan 2018 to 5.06% on 31 Dec 2018, a change of -0.20 percentage points. The year's high was 7.23% on 30 Apr 2018 and its low 4.16% on 15 Feb 2018, averaging 5.40% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.44 days on 31 May 2018. Full history: Intra-Cellular Therapies Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for Intra-Cellular Therapies Inc. in 2018

2018 in figures

Start of year
5.26% (12 Jan 2018)
End of year
5.06% (31 Dec 2018)
Change
-0.20 pp
High
7.23% (30 Apr 2018)
Low
4.16% (15 Feb 2018)
Average
5.40%
Highest days to cover
13.44 (31 May 2018)
SEC filings marked
8

Every report in 2018

Intra-Cellular Therapies Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 20185.26%4.34
31 Jan 20184.60%9.95
15 Feb 20184.16%4.73
28 Feb 20184.22%4.46
15 Mar 20185.33%3.2810-K filed, results (8-K)
29 Mar 20185.54%8.29
13 Apr 20186.59%5.62
30 Apr 20187.23%8.87
15 May 20186.89%9.8510-Q filed, results (8-K)
31 May 20186.49%13.44
15 Jun 20186.46%12.46
29 Jun 20186.20%6.74
13 Jul 20186.78%11.53
31 Jul 20185.88%8.72
15 Aug 20184.69%8.9610-Q filed, results (8-K)
31 Aug 20184.52%12.46
14 Sep 20184.36%11.71
28 Sep 20184.70%6.79
15 Oct 20185.29%8.07
31 Oct 20185.19%8.81
15 Nov 20184.58%7.7910-Q filed, results (8-K)
30 Nov 20184.72%7.13
14 Dec 20184.95%4.99
31 Dec 20185.06%5.49

See also: Intra-Cellular Therapies Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.